Results 131 to 140 of about 1,009 (151)

Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Journal of Clinical Oncology, 2021
e19043 Background: BPDCN is rare cancer commonly involving the skin and marrow. Tagraxofusp (Tag), a CD123 targeted therapy, was the first FDA approved drug for BPDCN in 2018. CNS involvement occurs in 10-60% of patients and CNS staging and prophylactic (ppx) practices are variable.
Irl Brian Greenwell, James Davis, Hong Li, Deborah Soong, Justin Taylor, Andrew A. Lane, David Rizzieri   +6 more
openaire   +1 more source

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancements in our patho-biologic understanding of the disease have led to the development of new targeted therapies for BPDCN.
Minas P, Economides, David, Rizzieri, Naveen, Pemmaraju   +2 more
openaire   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Blood, 2022
Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva   +12 more
openaire   +1 more source

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2016
The incorporation of Internet resources and the use of social media among patients, clinicians, advocates, and researchers in the field of hematology and oncology are growing in importance. Utilization of online information sharing is rising, especially among those involved in rare blood cancer fields, which have generally featured a paucity of ...
Pemmaraju, Naveen, Gupta, Vikas, Thompson, Michael A, Lane, Andrew A.   +3 more
openaire   +3 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDNC) is a rare tumour, which stems from plasmacytoid dendritic cells. Although the aetiology is still unclear, in the last few years various reports suggested a potential role of chromosomal aberrations in the oncogenesis.
A, Pileri, C, Delfino, V, Grandi, C, Agostinelli, S A, Pileri, N, Pimpinelli   +5 more
openaire   +1 more source

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Blood
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. The most commonly affected sites include the skin (65%), bone marrow (51%), and blood (45%).
Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie   +5 more
openaire   +1 more source

AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato Sergi, Dickran Kazandjian, Enrico Attardi, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Maria Teresa Voso, Mariam Abramashvili, Mazin Al-Jadiry, Michalis Michael, Nare Martirosyan, Nino Totogashvili, Pavel Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Gevorg Tamamyan, Naveen Pemmaraju   +30 more
openaire   +1 more source

Genetic Landscape of BPDCN Arising in CML Remission

Blood, 2022
Masataka Takeshita, Nobuyuki Kodama, Tomoko Hishima, Koji Okazaki, Akira Tanimura, Risen Hirai, Naomi Abe, Daisuke Kudo, Seishi Ogawa, Yasuhito Nannya, Akiyoshi Miwa   +10 more
openaire   +1 more source

POSTER: AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato Sergi, Dickran Kazandjian, Enrico Attardi, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Maria Teresa Voso, Mariam Abramashvili, Mazin Al-Jadiry, Michalis Michael, Nare Martirosyan, Nino Totogashvili, Pavel Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Gevorg Tamamyan, Naveen Pemmaraju   +30 more
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan malignancy defined by the WHO as affection fewer than 65 per 100,000 people and by the U.S. FDA as affecting less than 200,000 people in the U.S..
Astghik Voskanyan, Marina Konopleva, Maria Badikyan, Alvaro J Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M Sergi, Ching-Tien Peng, Dickran Kazandjian, Daniel Coriu, Funda Tekkesin, Justin Taylor, Hasanein Ghali, Hasmik Maghaqyan, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Min-Yu Su, Maria Camelia Stancioaica, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Najla H. Al Ali, Pavel P Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Shefali Mehra, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Ahmad Alhuraiji, Deniz Tuğcu, Gevorg Tamamyan, Naveen Pemmaraju, Rami S. Komrokji   +42 more
openaire   +1 more source